relugolix

structure in first source

Also Known As:

1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea; TAK 385; TAK-385; TAK385; orgovyx

Networked: 95 relevant articles (23 outcomes, 39 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Phenylurea Compounds: 1
      - relugolix: 95
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenylurea Compounds: 1
        relugolix: 95
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - relugolix: 95

Experts

1.	Shore, Neal D: 6 articles (07/2022 - 01/2020)
2.	Osuga, Yutaka: 6 articles (01/2022 - 01/2019)
3.	Kudou, Kentarou: 5 articles (10/2021 - 01/2019)
4.	Al-Hendy, Ayman: 4 articles (03/2022 - 01/2021)
5.	Tanimoto, Masataka: 4 articles (10/2021 - 01/2019)
6.	Saad, Fred: 4 articles (01/2021 - 12/2015)
7.	Li, Yulan: 3 articles (01/2022 - 01/2021)
8.	Wagman, Rachel B: 3 articles (01/2022 - 01/2021)
9.	Hoshiai, Hiroshi: 3 articles (10/2021 - 01/2019)
10.	Kusumoto, Takeru: 3 articles (10/2021 - 01/2021)

Related Diseases

1.	Leiomyoma (Uterine Fibroids) 01/01/2023 - "However, relugolix may be a safe and effective treatment option for patients with FIGO type 1 or 2 leiomyomas." 01/01/2023 - "Although there have been several studies on relugolix for leiomyomas, few have focused on submucosal leiomyomas. " 01/01/2023 - "A total of 17 patients were treated for submucosal leiomyoma with relugolix. " 01/01/2023 - "We retrospectively reviewed records of patients who underwent treatment for submucosal leiomyoma with relugolix (40 mg once daily for up to 6 months) in our institute between December 2019 and September 2021. " 10/28/2021 - "Relugolix decreased menstrual blood loss in women with uterine leiomyomas in a dose-response manner, and was generally well tolerated. "
2.	Menorrhagia 08/17/2023 - "Premenopausal women (aged 18-50 years) with UF-associated heavy menstrual bleeding (HMB) were randomized 1:1:1 in L1 (N = 388) and L2 (N = 382) to relugolix-CT or placebo for 24 weeks, or delayed relugolix-CT (relugolix 40 mg then relugolix-CT; 12 weeks each). " 12/01/2022 - "Among patients treated with relugolix combination therapy through 52 weeks (n=163), sustained improvement in heavy menstrual bleeding was observed in 87.7% (responders). " 12/01/2023 - "For women who had a relapse of heavy menstrual bleeding during the study (menstrual blood loss volume ≥80 mL), open-label relugolix combination therapy was offered. " 10/18/2023 - "In Black or African American women receiving continuous relugolix combination therapy for up to 52 weeks, 58 of 70 women (82.9%; 95% confidence interval, 72.0%-90.8%) met the treatment responder criteria for reduction in heavy menstrual bleeding (primary endpoint). " 10/18/2023 - "Once-daily relugolix combination therapy improved uterine fibroid-associated heavy menstrual bleeding in most Black or African American women who participated in the LIBERTY Long-Term Extension study. "
3.	Hemorrhage 01/01/2023 - "Participants on relugolix combination therapy showed a statistically significant reduction in symptom severity (-33.5 vs -12.1; nominal P<.0001) and the Bleeding and Pelvic Discomfort subscale from baseline to week 24 when compared with those on placebo treatment (-48.4 vs -17.4; nominal P<.0001). " 01/01/2023 - "Responder analyses demonstrated that more women treated with relugolix combination therapy reported a clinically meaningful reduction in the Bleeding and Pelvic Discomfort subscale and an improvement in physical and social activities when compared with those treated with the placebo (nominal P<.0001). " 04/01/2023 - "This is a summary of research studies (known as clinical trials) called LIBERTY 1 and LIBERTY 2. The LIBERTY 1 and LIBERTY 2 studies looked at how well a medication called relugolix combination therapy worked to reduce heavy bleeding at the time of menstruation compared with placebo. " 01/01/2023 - "Least squares mean changes from baseline to week 24 in the Symptom Severity scale, Bleeding and Pelvic Discomfort subscale, overall Health-Related Quality of Life scale, and the respective subscales were compared between the relugolix combination therapy and placebo groups. " 01/01/2021 - "Relugolix - new treatment for uterine fibroid-related heavy bleeding."
4.	Prostatic Neoplasms (Prostate Cancer) 01/01/2022 - "Based on the phase III HERO trial results, relugolix received Food and Drug Administration approval for adult patients with advanced prostate cancer (PCa). " 07/01/2023 - "Correction to: Relugolix: A Review in Advanced Prostate Cancer." 01/01/2023 - "A single institution retrospective chart review was conducted evaluating all patients who were prescribed relugolix for any prostate cancer indication from January 1, 2021 to January 31, 2022. " 01/01/2023 - "Relugolix: A Review in Advanced Prostate Cancer." 01/01/2023 - "We highlight concerns regarding the approval of relugolix for patients with prostate cancer. "
5.	Pain (Aches) 01/01/2022 - "The proportions of women with minimal-to-no pain during menstrual days and during nonmenstrual days were significantly higher with relugolix-CT (65.0% [95% CI 55.6-73.5] and 44.6% [95% CI 32.3-57.5], respectively) compared with placebo (19.3% [95% CI 13.2-26.7], nominal P<.001, and 21.6% [95% CI 12.9-32.7], nominal P=.004, respectively). " 01/01/2022 - "With relugolix-CT, 45.2% (95% CI 36.4-54.3) of women achieved minimal-to-no pain compared with 13.9% (95% CI 8.8-20.5) with placebo (nominal P<.001). " 11/01/2019 - "Similarly, more patients receiving relugolix versus placebo achieved a maximum NRS score of 0 (48.5% vs. 3.1%) and experienced more days without pain (96.4% vs. 71.4%). " 11/01/2023 - "Women taking relugolix combination therapy had less pelvic or groin pain during and between menstrual periods within 4 weeks of starting the medicine. " 04/01/2023 - "The women taking relugolix combination therapy also had less pain than those taking placebo. "

Related Drugs and Biologics

1.	Gonadotropin-Releasing Hormone (GnRH)
2.	Estradiol (Delestrogen)
3.	Testosterone (Sustanon)
4.	Norethindrone Acetate (Norlutate)
5.	Androgens
6.	Leuprolide (Lupron)
7.	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
8.	elagolix
9.	linzagolix
10.	Norethindrone (Norethisterone)

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Oral Administration
4.	Aftercare (After-Treatment)
5.	Retreatment